CRL vs. MEDP, INCY, ICLR, IQV, SWAV, KRTX, FMS, RVTY, RDY, and DVA
Should you be buying Charles River Laboratories International stock or one of its competitors? The main competitors of Charles River Laboratories International include Medpace (MEDP), Incyte (INCY), ICON Public (ICLR), IQVIA (IQV), Shockwave Medical (SWAV), Karuna Therapeutics (KRTX), Fresenius Medical Care (FMS), Revvity (RVTY), Dr. Reddy's Laboratories (RDY), and DaVita (DVA). These companies are all part of the "medical" sector.
Medpace (NASDAQ:MEDP) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medpace had 36 more articles in the media than Charles River Laboratories International. MarketBeat recorded 45 mentions for Medpace and 9 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.65 beat Medpace's score of 0.46 indicating that Medpace is being referred to more favorably in the media.
Charles River Laboratories International received 143 more outperform votes than Medpace when rated by MarketBeat users. However, 64.00% of users gave Medpace an outperform vote while only 61.57% of users gave Charles River Laboratories International an outperform vote.
Medpace has a net margin of 15.92% compared to Medpace's net margin of 11.49%. Charles River Laboratories International's return on equity of 59.74% beat Medpace's return on equity.
Medpace has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Medpace currently has a consensus target price of $443.00, suggesting a potential upside of 11.89%. Charles River Laboratories International has a consensus target price of $253.23, suggesting a potential upside of 10.57%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, equities analysts clearly believe Medpace is more favorable than Charles River Laboratories International.
78.0% of Medpace shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Medpace beats Charles River Laboratories International on 12 of the 18 factors compared between the two stocks.
Get Charles River Laboratories International News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charles River Laboratories International Competitors List
Related Companies and Tools
